ImmunoVaccine Up 24% On Deal With Gilead Sciences
February 27, 2015 at 12:50 PM EST
ImmunoVaccine Inc. (CVE: IMV) granted an exclusive development and commercialization license for its anthrax and Ebola vaccines ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.